AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Titan Pharmaceuticals Investor Alert: Kahn Swick & Foti Investigates Merger with KE Sdn. Bhd.
ByAinvest
Tuesday, Aug 5, 2025 9:26 pm ET1min read
Kahn Swick & Foti, LLC, a law firm led by former Louisiana Attorney General Charles C. Foti, is investigating Titan Pharmaceuticals' proposed merger with KE Sdn. Bhd. The firm is seeking to determine if the merger and process leading to it are adequate and fair to shareholders. If you have any concerns, you can contact Lewis S. Kahn at 855-768-1857 or visit their website for more information.
Kahn Swick & Foti, LLC, a law firm led by former Louisiana Attorney General Charles C. Foti, has initiated an investigation into Titan Pharmaceuticals, Inc.'s (TTNP) proposed merger with KE Sdn. Bhd. The firm is examining whether the merger and the process leading to it are adequate and fair to shareholders.Under the terms of the proposed merger, the existing security holders of KE and Titan expect to own approximately 86.7% and 13.3%, respectively, of the outstanding shares of the combined company. The investigation concerns whether the Titan Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders.
Lewis S. Kahn, Managing Partner of Kahn Swick & Foti, LLC, has stated that the firm is seeking to determine whether the consideration and the process that led to the merger are adequate or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn toll free at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-ttnp/ to learn more.
For further information, please visit Kahn Swick & Foti, LLC's website at https://www.ksfcounsel.com.
References:
[1] https://www.tradingview.com/news/reuters.com,2025-07-30:newsml_NFC2ncmLr:0-shareholder-notice-brodsky-smith-announces-an-investigation-of-titan-pharmaceuticals-inc-ttnp/
[2] https://www.marketscreener.com/news/performant-healthcare-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-ce7c5ed8d088f626
[3] https://www.morningstar.com/news/business-wire/20250805862253/hillevax-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-hillevax-inc-hlvx
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet